- Avalo Therapeutics Inc Annual Shareholders Meeting TranscriptDec 20, 2023
- Avalo Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Avalo Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 16, 2023
- Avalo Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Avalo Therapeutics Inc Annual Shareholders Meeting TranscriptJun 14, 2022
- Avalo Therapeutics Inc at Jefferies Next Generation IBD Therapeutics Summit (Virtual) - Pre-recorded Presentation TranscriptOct 19, 2021
- Cerecor Inc Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients - Corporate Call TranscriptJul 26, 2021
- Aytu BioScience Inc Acquires Prescription Product Portfolio from Cerecor Inc - M&A Call TranscriptOct 14, 2019
Cerecor Inc Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients - Corporate Call Transcript
Ladies and gentlemen, thank you for standing by and welcome to the Cerecor Initial Phase 1B Result for CERC-002 in Moderate to Severe Crohn's Disease Patients Conference Call.
At this time, all participants are in a listen-only mode. (Operator Instructions).
I would now like to turn the conference over to your speaker host today, Mr. Schond Greenway. Please go ahead.
Thank you, [Olivia]. Good day, everyone and thank you for joining us today to discuss the initial results from our Phase 1b proof of concept study evaluating CERC-002 at investigational first-in-class fully human anti-LIGHT monoclonal antibody in adult patients with moderate to severe Crohn's disease.
Speaking on the call today, we have Mike Cola, our Chief Executive Officer; Dr. Gary Neil, our Chief Scientific Officer; Dr. Jeffrey Wilkins, our Chief Medical Officer; and Dr. Gerald Dryden, Study Investigator and Professor of Medicine and Director of the Inflammatory Bowel Disease Program at the University of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)